Related Experiment Videos
Lipid-lowering agents in proteinuric diseases
American Journal of Nephrology
|January 1, 1990
Summary
Hyperlipidemia in kidney disease patients can worsen glomerular damage. Newer lipid-lowering drugs show promise in managing cholesterol levels without significant side effects.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Hyperlipidemia is prevalent in patients with glomerular proteinuria, potentially exacerbating atherosclerotic complications and kidney damage.
- Previous concerns regarding myositis with clofibrate led to hesitancy in treating nephrotic hyperlipidemia.
Purpose of the Study:
- To review the efficacy and safety of various lipid-lowering medications in patients with kidney disease and proteinuria.
- To assess the impact of these agents on lipid profiles and potential renal benefits.
Main Methods:
- Review of recent clinical trials and studies on lipid-lowering medications.
- Analysis of data on total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride levels.
- Evaluation of reported side effects and impact on proteinuria and glomerulosclerosis progression.
Main Results:
- Bile acid sequestrants (colestipol, cholestyramine) reduced total cholesterol by 8-20% and LDL by 19-31%.
- Probucol decreased total cholesterol by 23-30% and LDL by 23-25%, with a favorable LDL/HDL ratio despite HDL reduction.
- Gemfibrozil significantly lowered triglycerides and decreased total and LDL cholesterol by 13-15%, while increasing HDL by 18%.
- HMG-CoA reductase inhibitors reduced total cholesterol by 18-36% and LDL by 18-47%, with stable or increased HDL levels.
Conclusions:
- Several classes of lipid-lowering drugs are effective in improving lipid profiles in patients with kidney disease.
- While animal models suggest amelioration of glomerular damage, human trials have not yet established a clear benefit on proteinuria or glomerulosclerosis progression.